Celgene shares hit another high; Fat CEOs not perceived as leadership heavyweights;

@FiercePharma: Pfizer settles bellwether Chantix case ahead of next week's trial date. Amount undisclosed. More | Follow @FiercePharma

 @AlisonBFierce: WHO says dengue is the world's fastest-spreading tropical disease. GSK's dengue vaccine flopped in trials last year. News | Follow @AlisonBFierce

> Shares of drugmaker Celgene ($CELG) hit a seventh consecutive high of $99.39 Wednesday after Bank of America - Merrill Lynch upgraded its rating to buy. Item

> The FDA has released its fee rates for generic drug and API makers with foreign plants paying a $15,000 premium to cover the added costs of inspecting those facilities. Q & A

> A report says that the U.K. drug pricing agency National Institute for Health and Clinical Excellence (NICE) needs to get on the stick if its move to value pricing is to go smoothly, and also is recommending the agency provide more transparency on the results from clinical trials. Story

> Pharmacy chains CVS Caremark ($CVS)"and Rite Aid ($RAD) are both having trouble keeping enough flu vaccine on hand in some markets as the flu season kicks into higher gear. Story

> Ranbaxy Laboratories and its parent Daiichi Sankyo have decided to merge their management operations in Thailand, where each company is currently focused on different parts of that growing market. Story

> A Wisconsin report has raised fears that most unused medicines are getting dumped down the toilet even as the cost of programs for recycling are getting more expensive for governments. Story

Medical Device News

 @FierceMedDev: Quest takes $89.5M hit as it plots sale of Dx products unit. Report | Follow @FierceMedDev

@MarkHFierce: SV Bio says it is trying simplify gene sequencing for every day Dx purposes . System should be ready for market soon. Report | Follow @MarkHFierce

 @DamianFierce: And, finally, $COV has a renal denervation device on the market overseas. Story | Follow @DamianFierce

> Luminex grabs FDA clearance for stomach bug diagnostic. News

> Illumina ($ILMN)  @FierceBiotech: Takeda's R&D boss infuses 'urgency' into Japan's No. 1 drugmaker. Editor's Corner | Follow @FierceBiotech

@JohnCFierce: Buzz: AstraZeneca reorganization inspires fresh rumors of Shire bid. Story | Follow @JohnCFierce

@RyanMFierce: Pharma fumbles in recruitment game as clinical trials miss goals. Article | Follow @RyanMFierce

> Big Pharma drives R&D push for new drugs to treat neglected diseases. Report

> Bristol-Myers ($BMY) begins pricey post-mortem cleanup following 094 disaster. Story

Drug Delivery News

> Pfizer ($PFE) launches first U.S. once-daily liquid ADHD drug. Article

> Clearside plans to move microinjections into clinic. Report

> BioTime seeks EU support for stem cell delivery gel. Story

> Aussie nanopatch offers new way to vaccinate. Item

> Bayer's extended use IUD nets FDA go-ahead. News

And Finally... Anyone with an eye on the C-suite better be sure they have a gym membership because new research suggests that executives carrying extra weight are perceived to not be as effective as their hard-body peers. Story (sub. req.)
 

Suggested Articles

J&J's talc woes deepened Friday after the FDA turned up "sub-trace" levels of asbestos one bottle of the company's baby powder,…

Another major drugmaker is recalling in the U.K. 10 batches of its Zantac generics because they contain a possible carcinogen.

With diagnosis rates on the rise, Pfizer's Vyndaqel franchise could collect $157 million in 2019 U.S. sales, well above consensus, SVB Leerink says.